MAR-DONEPEZIL TABLET
Država: Kanada
Jezik: engleski
Izvor: Health Canada
Svojstava lijeka
(SPC)
10-02-2020
Neki dokumenti za ovaj proizvod trenutno nisu dostupni, možete poslati zahtjev u našu korisničku službu i mi ćemo vas obavijestiti čim ih budemo mogli dobiti.
Pošalji zahtjev.
Pošalji zahtjev.
Aktivni sastojci:
DONEPEZIL HYDROCHLORIDE
Dostupno od:
MARCAN PHARMACEUTICALS INC
ATC koda:
N06DA02
INN (International ime):
DONEPEZIL
Doziranje:
10MG
Farmaceutski oblik:
TABLET
Sastav:
DONEPEZIL HYDROCHLORIDE 10MG
Administracija rute:
ORAL
Jedinice u paketu:
100/500
Tip recepta:
Prescription
Područje terapije:
PARASYMPATHOMEMETIC (CHOLINERGIC) AGENTS
Proizvod sažetak:
Active ingredient group (AIG) number: 0131548002; AHFS:
Status autorizacije:
APPROVED
Datum autorizacije:
2013-12-27
Svojstava lijeka
Page 1 of 50
PRODUCT MONOGRAPH
Pr
MAR-DONEPEZIL
Donepezil Hydrochloride Tablets, House Std
5 and 10 mg
CHOLINESTERASE INHIBITOR
Marcan Pharmaceuticals Inc. Date of Revision:
2 Gurdwara Road, Suite 112
February 10, 2020
Ottawa, Ontario
K2E 1A2
Submission Control No.: 235582
Page 2 of 50
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................... 3
SUMMARY PRODUCT INFORMATION
.......................................................................
3
INDICATIONS AND CLINICAL USE
.............................................................................
3
CONTRAINDICATIONS
..................................................................................................
3
WARNINGS AND PRECAUTIONS
.................................................................................
3
ADVERSE REACTIONS
...................................................................................................
7
DRUG INTERACTIONS
.................................................................................................
16
DOSAGE AND ADMINISTRATION
.............................................................................
17
OVERDOSAGE
...............................................................................................................
18
ACTION AND CLINICAL PHARMACOLOGY
........................................................... 18
STORAGE AND STABILITY
.........................................................................................
21
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................ 21
PART II: SCIENTIFIC INFORMATION
...............................................................................
22
PHARMACEUTICAL INFORMATION
.........................................................................
22
CLINICAL TRIALS
.........................................................................................................
24
DETAILED PHARMACOLOGY
...................................................................
Pročitajte cijeli dokument
